Thrombosis  /  Future Human Burden

Each year around 75,000 Americans are diagnosed with atrial fibrillation (AFib), 900,000 experience a venous thromboembolism event (VTE), and 800,000 have a stroke. The burden for those who survive is enormous and the cost of care a major expense for individuals and the nation. Fortunately research advances are offering significant hope. A number of investigative anticoagulants have the potential to reduce strokes in AFib patients while also reducing the risk of bleeds; clot-dissolving agents are proving to lessen the effects of strokes; and the same drugs in the pipeline for AFib could prevent VTE after major orthopedic surgery.

6 Matching Facts

Search matching Facts:
No results to display
    • Atrial fibrillation prevalence projection, 2050
      Atrial fibrillation prevalence is projected to rise to between 5.6 and 12.1 million in 2050.  
    • Predicted incidence of VTE, 2050
      The incidence of VTE is predicted to more than double by 2050—from 0.95 million in 2006 to 1.82 million in 2050.  
    • AFib patients over age 80, 2050
      By 2050, it is estimated that more than 50% of Americans with atrial fibrillation will be age 80 and older.  
    • AFib prevalence rate projection, 2050
      By 2050, it is estimated that 88% of Americans with atrial fibrillation will be age 65 and older.  
    • Projected AFib incidence, 2050
      If current incidence estimates are applied to Census Bureau projections, by 2050 the number of Americans with atrial fibrillation could exceed 12 million. If increases in incidence continue, that number could…  
    • AFib prevalence projected to double by 2050
      By 2050, the prevalence of atrial fibrillation will have more than doubled since 2001—growing to an estimated 5.6 million to 12.1 million Americans.